“The rap on St. Louis’ biotech industry is that all of its startups are years away from selling products, with no big success stories yet.

Don’t tell that to Ed Weinstein, co-founder and chief executive of Canopy Biosciences. Canopy is launching its first product just months after being founded, and it expects to quickly achieve profitability. Moreover, Weinstein has already achieved the kind of lucrative exit that’s rare in St. Louis.”

“Canopy specializes in tools for genetic engineering, molecular biology and personalized medicine. Its first product, licensed from Washington University, is a chemical kit that allows scientists to fine-tune a gene they’re interested in.

Key research on the technology, called Tunr, was just published in January. Canopy already had it under license and will introduce Tunr next month at a cancer research conference.”

Read the entire article.


Start typing and press Enter to search